secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-12-14T23:59:59+00:00
Accession:  0001140361-23-057578
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant closes $7.1B sale of Telavant to Roche; retains 75% ownership prior to closing
--------------------------------------------------------------------------------

- Total upfront cash consideration of approximately $7.1 billion paid to Telavant equity holders.
- Roivant owned 75% of Telavant on an as-converted basis before the transaction closed.
- Additional $150 million cash milestone payable upon initiation of a Phase 3 ulcerative colitis trial.
- Telavant holds US and Japan rights to TL1A antibody RVT-3101 for IBD and Crohn's disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/0001140361-23-057578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/ef20016626_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-057578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer